Early Parkinson’s: 3-Year Study Tracks Decline with Wearables & Patient Data

A modern study published in the Journal of Neurology is offering valuable insights into the progression of early Parkinson’s disease (PD), revealing that functional impairment continues to worsen even when specific symptoms appear stable. The research, led by Jamie Adams, M.D. And Jennifer Mammen, Ph.D., utilized wearable devices and patient-reported data collected over three years to track changes in individuals newly diagnosed with the condition. This approach underscores the importance of considering real-world experiences alongside traditional clinical assessments when evaluating the impact of Parkinson’s and designing clinical trials.

The study, titled “Three years later: tracking bothersome symptoms and impacts for people with early Parkinson’s disease,” followed participants prospectively, meaning they were observed over time as the disease naturally progressed. Researchers found that gait, balance, and posture were consistently reported as the most troublesome issues, and the effort required for daily activities increased significantly, contributing to a growing psychosocial burden. This suggests that even subtle declines in function can have a substantial impact on quality of life.

The Patient’s Voice and Real-World Measurement

Dr. Adams, the study’s senior author, emphasized the collaborative nature of the research and the importance of integrating the patient perspective. “We have championed the integration of the patient voice from the incredibly beginning and seeing these perspectives formally shape the scientific record feels like the culmination of a deep and long-term partnership that has fundamentally changed how we approach clinical observation,” she said. This focus on the patient experience is a key element of the operate conducted by Critical Path Institute’s (C-Path) Critical Path for Parkinson’s consortium, which partnered on the study.

A significant aspect of the study’s methodology was the use of wearable devices. These devices allowed researchers to gather objective data on participants’ movements and activity levels in their everyday environments, providing a more comprehensive picture of disease progression than traditional clinic-based assessments alone. Wearable technology is increasingly being used in Parkinson’s research to capture nuanced changes in motor function that might otherwise go unnoticed.

Beyond Symptoms: Functional Impairment

The findings highlight a crucial distinction between symptom management and functional impairment. While treatments may successfully address specific symptoms, the study demonstrates that overall functional ability – the capacity to perform daily tasks – can continue to decline even when symptoms appear stable. This underscores the need for a more holistic approach to assessing disease progression and evaluating the effectiveness of potential therapies.

This represents particularly relevant to clinical trial design. Diane Stephenson, Ph.D., C-Path Vice President of Neurology and Executive Director of the Critical Path for Parkinson’s consortium, explained, “At C-Path, our goal is to put robust and patient-centered measurement tools directly in the hands of drug developers so they can design the very best clinical trials.” Incorporating real-world measures of disease progression, like those obtained through wearable devices and patient-reported outcomes, can support ensure that clinical trials accurately reflect the experiences of people living with Parkinson’s.

Digital Health and the Future of Parkinson’s Research

The study also points to the growing potential of digital health technologies in Parkinson’s research. Combining data from wearable sensors with patient interviews provides a more complete understanding of how the disease impacts individuals’ lives. Digital measures can capture objective data on movement and activity, while patient interviews provide valuable context and insights into the subjective experiences of living with the condition.

Cheryl Coon, Ph.D., Vice President of C-Path’s Clinical Outcome Assessment Program, noted that integrating measures of gait and balance with longitudinal patient-reported assessment offers a powerful method to monitor disease progression. This approach aligns with C-Path’s core competencies in patient-focused drug development.

The Importance of Lived Experience

The study’s success is also attributed to the active involvement of people living with Parkinson’s disease in the research process. Sarah Zenner Dolan, a research participant with early-onset Parkinson’s, emphasized the importance of C-Path’s focus on the patient voice. “C-Path’s focus on the voice of people living with Parkinson’s disease is a key north star and critical in the evaluation of how wearable devices can reliably track our symptoms in real time,” she said.

Yuge Xiao, Clinical Research Lead at The Michael J. Fox Foundation for Parkinson’s Research, added that combining digital measures with participant interviews ensures a clear link between the data collected and the changes that matter most to people with Parkinson’s. The Michael J. Fox Foundation funded the research with grants #MJFF-024503 and # MJFF-022743.

What’s Next: Refining Clinical Trials

The findings from this study are expected to inform the design of future clinical trials for Parkinson’s disease. By incorporating real-world measures of disease progression and prioritizing the patient perspective, researchers can develop more effective therapies that address the challenges faced by individuals living with the condition. The study’s authors suggest that continued research is needed to refine these measurement tools and to identify biomarkers that can predict disease progression. Critical Path Institute plans to continue its work in this area, focusing on the development of patient-centered measurement tools and the acceleration of drug development for Parkinson’s disease. Further investigation into the psychosocial burden associated with Parkinson’s is also warranted, as this study highlights the significant impact of the disease on quality of life.

Individuals concerned about Parkinson’s disease are encouraged to consult with a qualified healthcare professional for diagnosis and management. More information about Parkinson’s disease and ongoing research can be found on the websites of organizations such as the Michael J. Fox Foundation for Parkinson’s Research and the Parkinson’s Foundation.